SCINTOMICS Molecular (att) Applied Theranostics Technologies GmbH
ATT - SCINTOMICS Molecular Applied Theranostics Technologies
ATT (SCINTOMICS Molecular, Applied Theranostics Technologies) is a recently founded German company specialized to supply and support the PET and SPECT community with peptides, intermediates and consumables dedicated to the concept of theranostics. As a worldwide operating subsidiary of Scintomics, ATT continues and expands Scintomics ́ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics proprietary and innovative tracer technology and non-IP protected precursors. The founders have more than 25 years of experience in Radiopharmaceutical Chemistry and Nuclear Medicine.
ATT offers a broad range of highly innovative targeted agents for cancer imaging, including ground breaking silicon-based F-18 labeled PSMA inhibitors that are produced in clinical settings in <1000sec, PSMA-inhibitors for radioligand therapy, such as PSMA I&T (patent protected is several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy, such as PSMA TO-1. ATT also offers customized packages comprising of dedicated GMP compliant production modules, GMP- cassettes/consumables and precursors. ATT and Scintomics continues to further expand the outstanding pipeline of innovative products for theranostic applications.
Brands: ATT and Scintomics continues to further expand the outstanding pipeline of innovative products for theranostic applications.